What's new — Ischemic heart disease¶
Generated 2026-11-01 from the publication dates of every paper cited in this condition's pages.
This page answers a different question from the curation log. The log says when we last edited a page; this says how recent the evidence on those pages is — so you can tell settled ground from a field that is actively moving, and jump straight to what has emerged lately.
How much of this condition's evidence is recent¶
| Published within | Cited papers |
|---|---|
| last week | 1 |
| last month | 5 |
| last 2 months | 12 |
| last 3 months | 23 |
| last 6 months | 24 |
| last year | 30 |
| older than a year | 247 |
Counts are cumulative: a paper from last week also counts inside "last month". Dates are PubMed publication or e-publication dates, so a paper may have appeared online before its journal issue.
Newest evidence first¶
The most recent cited papers, with the pages that use them.
| Published | Paper | Cited on |
|---|---|---|
| 2026-10-26 | Fifth Universal Definition of Myocardial Infarction (2026) — Eur Heart J ([PMID 42661425](https://pubmed.ncbi.nlm.nih.gov/42661425/){target="_blank" rel="noopener"}) | acute-coronary-syndromes, guidelines |
| 2026-10-23 | 2026 ESC Guidelines on cardiac rehabilitation — Eur Heart J ([PMID 42661418](https://pubmed.ncbi.nlm.nih.gov/42661418/){target="_blank" rel="noopener"}) | cardiac-rehabilitation-and-lifestyle, guidelines |
| 2026-10-05 | The Comorbidity-Driven Interleukin-6-Mediated Systemic Inflammation Hypothesis of Heart Failure With Preserved Ejection Fraction: A Decade of Testing Ends in Disappointment — J Card Fail ([PMID 42833572](https://pubmed.ncbi.nlm.nih.gov/42833572/){target="_blank" rel="noopener"}) | inflammation-and-residual-risk |
| 2026-10-02 | Correction to: 2026 ESC Guidelines on cardiac rehabilitation: Developed by the task force on cardiac rehabilitation of the European Society of Cardiology (ESC)Endorsed by the European Society of Physical and Rehabilitation Medicine (ESPRM) and World Organization of Family Doctors (WONCA) — Eur Heart J ([PMID 42921976](https://pubmed.ncbi.nlm.nih.gov/42921976/){target="_blank" rel="noopener"}) | cardiac-rehabilitation-and-lifestyle, guidelines |
| 2026-10-02 | Correction: Fifth Universal Definition of Myocardial Infarction (2026): On behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial InfarctionEndorsed by the European Association for Cardio-Thoracic Surgery (EACTS) and the Society of Thoracic Surgeons (STS)Affirmation of Value by the Society for Cardiovascular Angiography and Interventions (SCAI) — Eur Heart J ([PMID 42905436](https://pubmed.ncbi.nlm.nih.gov/42905436/){target="_blank" rel="noopener"}) | acute-coronary-syndromes, guidelines |
| 2026-10-01 | ICare-FASTER (Improving Care by Faster Risk Stratification Through Use of High-Sensitivity Point-of-Care Troponin in Patients Presenting With Possible Acute Coronary Syndrome in the Emergency Department): A Stepped-Wedge Cluster-Randomized Trial — Circulation ([PMID 42895015](https://pubmed.ncbi.nlm.nih.gov/42895015/){target="_blank" rel="noopener"}) | biomarkers |
| 2026-10-01 | Pelacarsen and Lp(a)HORIZON: Interpreting the Disconnect Between Lipoprotein(a) Lowering and Cardiovascular Outcomes — Am J Med ([PMID 42880684](https://pubmed.ncbi.nlm.nih.gov/42880684/){target="_blank" rel="noopener"}) | biomarkers, clinical-trials-landscape, guidelines, inflammation-and-residual-risk, lipid-lowering |
| 2026-10-01 | Interventions to Promote Utilisation of Cardiac Rehabilitation: 2026 Cochrane Systematic Review and Meta-Analysis — Heart Lung Circ ([PMID 42823225](https://pubmed.ncbi.nlm.nih.gov/42823225/){target="_blank" rel="noopener"}) | cardiac-rehabilitation-and-lifestyle |
| 2026-09-08 | Correction to: 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines — Circulation ([PMID 42709919](https://pubmed.ncbi.nlm.nih.gov/42709919/){target="_blank" rel="noopener"}) | guidelines |
| 2026-09-03 | Geographic heterogeneity in outcomes of intravascular ultrasound-guided vs angiography-guided percutaneous coronary intervention: a meta-analysis of randomized trials — Eur Heart J ([PMID 42690150](https://pubmed.ncbi.nlm.nih.gov/42690150/){target="_blank" rel="noopener"}) | revascularization-pci-and-cabg |
| 2026-09-01 | Exercise-based cardiac rehabilitation for coronary heart disease — Cochrane Database Syst Rev ([PMID 42754260](https://pubmed.ncbi.nlm.nih.gov/42754260/){target="_blank" rel="noopener"}) | cardiac-rehabilitation-and-lifestyle |
| 2026-09-01 | Intracoronary Imaging-Guided Percutaneous Coronary Intervention: An Updated Meta-Analysis of Randomized Trials — J Am Coll Cardiol ([PMID 42747372](https://pubmed.ncbi.nlm.nih.gov/42747372/){target="_blank" rel="noopener"}) | revascularization-pci-and-cabg |
| 2026-08-25 | Global Burden of Elevated LDL-C: Findings From the Global Burden of Disease Study 2023 — JAMA ([PMID 42525403](https://pubmed.ncbi.nlm.nih.gov/42525403/){target="_blank" rel="noopener"}) | biomarkers, epidemiology-and-global-burden, lipid-lowering, overview |
| 2026-08-03 | Protocol-Based Implementation of Early Intensive Lipid Management After Acute Coronary Syndrome: The BRIDGE Trial — J Am Coll Cardiol ([PMID 42671370](https://pubmed.ncbi.nlm.nih.gov/42671370/){target="_blank" rel="noopener"}) | lipid-lowering |
| 2026-08-03 | Effects of Evolocumab on Mortality Outcomes in Patients Without Previous Myocardial Infarction or Stroke: A Prespecified Analysis of the VESALIUS-CV Randomized Clinical Trial — Circulation ([PMID 42670293](https://pubmed.ncbi.nlm.nih.gov/42670293/){target="_blank" rel="noopener"}) | lipid-lowering |
| 2026-08-03 | Antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation: an individual patient data network meta-analysis — Eur Heart J ([PMID 42669062](https://pubmed.ncbi.nlm.nih.gov/42669062/){target="_blank" rel="noopener"}) | antithrombotic-therapy |
| 2026-08-02 | Complete Revascularization Guided by Functional Coronary Angiography in STEMI — N Engl J Med ([PMID 42670979](https://pubmed.ncbi.nlm.nih.gov/42670979/){target="_blank" rel="noopener"}) | acute-coronary-syndromes |
| 2026-08-02 | Milvexian with Antiplatelet Therapy after Acute Coronary Syndrome Event — N Engl J Med ([PMID 42670965](https://pubmed.ncbi.nlm.nih.gov/42670965/){target="_blank" rel="noopener"}) | clinical-trials-landscape |
| 2026-08-02 | Vericiguat for the Treatment of Coronary Vasospasm (ViVA): A Double-Blind Placebo-Controlled Randomized Crossover Trial — J Am Coll Cardiol ([PMID 42670734](https://pubmed.ncbi.nlm.nih.gov/42670734/){target="_blank" rel="noopener"}) | inoca-and-special-phenotypes |
| 2026-08-02 | Dual antithrombotic therapy using potent antiplatelet inhibitors in atrial fibrillation and acute coronary syndrome: a randomized controlled trial — Nat Med ([PMID 42668287](https://pubmed.ncbi.nlm.nih.gov/42668287/){target="_blank" rel="noopener"}) | antithrombotic-therapy |
| 2026-08-02 | Safety and efficacy of the 0/1 h pathway for myocardial infarction in the emergency department: an international, pragmatic, stepped-wedge, cluster-randomised, controlled trial — Lancet ([PMID 42667934](https://pubmed.ncbi.nlm.nih.gov/42667934/){target="_blank" rel="noopener"}) | biomarkers |
| 2026-08-02 | Fifth Universal Definition of Myocardial Infarction (2026): On behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS) and the Society of Thoracic Surgeons (STS) Affirmation of Value by the Society for Cardiovascular Angiography and Interventions (SCAI) — Glob Heart ([PMID 42666939](https://pubmed.ncbi.nlm.nih.gov/42666939/){target="_blank" rel="noopener"}) | acute-coronary-syndromes, biomarkers, guidelines, inoca-and-special-phenotypes |
| 2026-08-02 | LDL Cholesterol Lowering With Evolocumab Before Percutaneous Coronary Intervention for Acute Myocardial Infarction: The AMUNDSEN Randomized Clinical Trial — JAMA ([PMID 42666092](https://pubmed.ncbi.nlm.nih.gov/42666092/){target="_blank" rel="noopener"}) | lipid-lowering |
| 2026-06-02 | Correction to: 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines — Circulation ([PMID 42330109](https://pubmed.ncbi.nlm.nih.gov/42330109/){target="_blank" rel="noopener"}) | guidelines |
| 2026-05-02 | Concordance of Lipoprotein(a) measurements in mg/dL and nmol/L: Insights from the Lp(a)HORIZON trial — Atherosclerosis ([PMID 42250319](https://pubmed.ncbi.nlm.nih.gov/42250319/){target="_blank" rel="noopener"}) | guidelines |
| 2026-05-02 | Accelerated Diagnostic Pathways for Suspected Acute Coronary Syndrome in Practice: A Randomized Trial of 0/1-Hour vs 0/3-Hour Troponin Testing — J Am Coll Cardiol ([PMID 42159533](https://pubmed.ncbi.nlm.nih.gov/42159533/){target="_blank" rel="noopener"}) | biomarkers |
| 2026-03-01 | 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines — Circulation ([PMID 41824552](https://pubmed.ncbi.nlm.nih.gov/41824552/){target="_blank" rel="noopener"}) | guidelines, lipid-lowering |
| 2026-01-01 | Rationale, Design, and Baseline Clinical Characteristics of the Ziltivekimab Cardiovascular Outcomes Trial: Interleukin-6 Inhibition and Atherosclerotic Event Rate Reduction — JAMA Cardiol ([PMID 41369941](https://pubmed.ncbi.nlm.nih.gov/41369941/){target="_blank" rel="noopener"}) | inflammation-and-residual-risk |
| 2025-11-08 | Evolocumab in Patients without a Previous Myocardial Infarction or Stroke — N Engl J Med ([PMID 41211925](https://pubmed.ncbi.nlm.nih.gov/41211925/){target="_blank" rel="noopener"}) | lipid-lowering |
| 2025-11-01 | Effect of low-dose colchicine on pericoronary inflammation and coronary plaque composition in chronic coronary disease: a subanalysis of the LoDoCo2 trial — Heart ([PMID 40393691](https://pubmed.ncbi.nlm.nih.gov/40393691/){target="_blank" rel="noopener"}) | inflammation-and-residual-risk, pathophysiology-and-plaque-biology |
Trials — what has moved¶
23 registered trials are cited by this condition's pages. Registry records were re-checked live when this page was generated, so status, enrolment and results-posting below reflect ClinicalTrials.gov as of that date.
| Registry activity | Trials |
|---|---|
| trial records updated in the last week | 1 |
| trial records updated in the last month | 2 |
| trial records updated in the last 2 months | 6 |
| trial records updated in the last 3 months | 8 |
| trial records updated in the last 6 months | 10 |
| trial records updated in the last year | 14 |
Recently updated registrations¶
| Updated | Trial | Phase | Status | N | Cited on |
|---|---|---|---|---|---|
| 2026-10-27 | Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcom | PHASE3 | ACTIVE_NOT_RECRUITING | 7297 | biomarkers, clinical-trials-landscape, guidelines, inflammation-and-residual-risk, lipid-lowering |
| 2026-10-19 | The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C) | NA | RECRUITING | 754 | clinical-trials-landscape, revascularization-pci-and-cabg |
| 2026-10-01 | Precision Colchicine Intervention to Suppress Atherosclerosis in TET2 Clonal Hematopoiesis | PHASE4 | RECRUITING | 120 | clinical-trials-landscape, inflammation-and-residual-risk |
| 2026-10-01 | A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Hear | PHASE3 | TERMINATED | 4874 | inflammation-and-residual-risk |
| 2026-09-28 | ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People Wi | PHASE3 | COMPLETED | 6385 | clinical-trials-landscape, inflammation-and-residual-risk |
| 2026-09-09 | ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People | PHASE3 | ACTIVE_NOT_RECRUITING | 10000 | clinical-trials-landscape, inflammation-and-residual-risk |
| 2026-08-28 | Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiov | PHASE3 | COMPLETED | 8323 | biomarkers, clinical-trials-landscape, guidelines, inflammation-and-residual-risk, lipid-lowering |
| 2026-08-17 | Coronary Sinus Reducer Implantation in Patients With Ischaemia and Non-obstructed Coronary | NA | ACTIVE_NOT_RECRUITING | 54 | clinical-trials-landscape, inoca-and-special-phenotypes |
| 2026-07-06 | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome | PHASE3 | COMPLETED | 14194 | clinical-trials-landscape |
| 2026-06-12 | Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Change in Cardi | NA | ACTIVE_NOT_RECRUITING | 200 | clinical-trials-landscape |
| 2026-04-14 | Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Plac | PHASE4 | COMPLETED | 1770 | clinical-trials-landscape |
| 2026-03-30 | Ischemic Postconditioning in STEMI Patients Treated With Primary PCI | NA | RECRUITING | 1800 | clinical-trials-landscape |
| 2026-03-11 | A Research Study to Look at the Effect of Ziltivekimab on Plaque in the Blood Vessels of t | PHASE3 | RECRUITING | 332 | clinical-trials-landscape, inflammation-and-residual-risk |
| 2026-01-02 | ISCHEMIA-CTO Trial - Revascularisation or Optimal Medical Therapy of CTO | NA | RECRUITING | 1560 | clinical-trials-landscape |
Posted efficacy and safety results¶
Trials whose sponsors have posted results to the registry. Adverse-event figures are participant counts summed across all arms as reported — read them against enrolment, and follow the registry link for the arm-by-arm breakdown that determines whether a signal is real.
| Results posted | Trial | Phase | N | Primary outcome | Serious AE | Other AE | Deaths |
|---|---|---|---|---|---|---|---|
| 2026-04-14 | Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisi | PHASE4 | 1770 | Number of Participants Achieving Individual LDL-C Target (<55 mg/dL or | 592 | 1756 | 22 |
12 of these trials are still recruiting or active — see the condition's clinical trials page for the full landscape.
Which pages rest on the newest evidence¶
🔥 marks a page citing three or more papers from the last year — the pages worth re-reading if you have been away.
| Page | Newest citation | In last year | Total citations |
|---|---|---|---|
| acute-coronary-syndromes | 2026-10-26 | 4 | 33 |
| guidelines | 2026-10-26 | 10 | 41 |
| cardiac-rehabilitation-and-lifestyle | 2026-10-23 | 4 | 33 |
| inflammation-and-residual-risk | 2026-10-05 | 4 | 32 |
| biomarkers | 2026-10-01 | 6 | 34 |
| clinical-trials-landscape | 2026-10-01 | 2 | 32 |
| lipid-lowering | 2026-10-01 | 7 | 35 |
| revascularization-pci-and-cabg | 2026-09-03 | 2 | 31 |
| epidemiology-and-global-burden | 2026-08-25 | 1 | 29 |
| overview | 2026-08-25 | 1 | 38 |
| antithrombotic-therapy | 2026-08-03 | 2 | 31 |
| inoca-and-special-phenotypes | 2026-08-02 | 2 | 31 |
| pathophysiology-and-plaque-biology | 2025-11-01 | 1 | 31 |
| patient-experience-and-advocacy | 2025-09-02 | 0 | 29 |
| stable-cad-management | 2025-05-13 | 0 | 29 |
| red-flags-and-safety-concerns | 2025-02-02 | 0 | 31 |
Recency is not quality: an old paper may be the definitive one, and a new paper may not replicate. Use this to find movement, not to rank evidence. See open questions for what remains unresolved, and the curation log for when these pages were last revised.